Skip to main content
Log in

Ganzheitliche Behandlung der chronischen Herzinsuffizienz

Holistic therapy of chronic heart failure

  • Schwerpunkt
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Die zunehmende Prävalenz und steigende krankheitsbedingte Kosten machen die chronische Herzinsuffizienz zu einer wachsenden sozioökonomischen Herausforderung. Nur durch ein therapeutisches Zusammenwirken von leitliniengerechter Herzinsuffizienztherapie und ganzheitlicher Patientenbetreuung können Mortalität, Morbidität, Leistungsfähigkeit und Lebensqualität verbessert werden. Eine ganzheitliche Patientenversorgung beinhaltet neben der medikamentösen und chirurgischen Therapie die Berücksichtigung von Komorbiditäten und individuellen Bedürfnissen, Lebensstilberatung und multidisziplinäre Managementprogramme bei Hochrisikopatienten. Darüber hinaus ist für eine optimale Patientenbetreuung wichtig, dass eine „nahtlose“ stationäre und ambulante Versorgungsstruktur gewährleistet wird. Bei Herzinsuffizienzpatienten müssen auch palliative Bedürfnisse berücksichtigt werden, die derzeit noch zu wenig Beachtung finden.

Abstract

The rising prevalence and increasing disease-related costs render chronic heart failure a rapidly growing socioeconomic challenge. The concerted action of guideline-adjusted therapy and holistic patient care is essential to achieve improvements in mortality, morbidity, functional status and quality of life of patients with symptomatic heart failure. Holistic care strategies comprise consideration of comorbidities and individual needs, lifestyle recommendations and multidisciplinary management programs for high-risk symptomatic patients in addition to basic medication and surgical therapies. For optimal patient care and coaching, seamless interaction is required between in-hospital treatment and outpatient facilities. Moreover, the palliative needs of heart failure patients need to be considered, a topic that is currently not receiving enough attention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Angermann CE, Gelbrich G, Stork S et al (2007) Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail 9:1212–1222

    Article  CAS  PubMed  Google Scholar 

  2. Angermann CE, Stork S, Gelbrich G et al (2012) Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the Interdisciplinary Network for Heart Failure (INH) study. Circ Heart Fail 5:25–35

    Article  PubMed  Google Scholar 

  3. Anker SD, Comin Colet J, Filippatos G et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436–2448

  4. Palliative Care Alliance and World Health Organization (2014) Global Atlas of Palliative Care at the End of Life

  5. World Health Organization (o J) WHO definition of palliative care

  6. Braunstein JB, Anderson GF, Gerstenblith G et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42:1226–1233

  7. Brenner S, Guder G, Berliner D et al (2013) Airway obstruction in systolic heart failure – COPD or congestion? Int J Cardiol 168:1910–1916

    Article  PubMed  Google Scholar 

  8. Cleland JG, Cohen-Solal A, Aguilar JC et al (2002) Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 360:1631–1639

    Article  CAS  PubMed  Google Scholar 

  9. Ekman I, Chassany O, Komajda M et al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32:2395–2404

    Article  Google Scholar 

  10. Faller H, Angermann CE (2008) Depression in chronic heart failure: complication, risk factor or autonomous disease? Internist (Berl) 49:394, 396–398, 400, 402–404

  11. Ghoorah K, Campbell P, Kent A et al (2014) Obesity and cardiovascular outcomes: a review. Eur Heart J Acute Cardiovasc Care (im Druck)

  12. Gielen S, Landmesser U (2014) The year in cardiology 2013: cardiovascular disease prevention. Eur Heart J 35:307–312

    Article  Google Scholar 

  13. Goodlin SJ (2009) Palliative care in congestive heart failure. J Am Coll Cardiol 54:386–396

  14. Hernandez AV, Usmani A, Rajamanickam A et al (2011) Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11:115–128

    Article  CAS  PubMed  Google Scholar 

  15. Jaarsma T, Beattie JM, Ryder M et al (2009) Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11:433–443

    Article  PubMed  Google Scholar 

  16. Klip IT, Comin-Colet J, Voors AA et al (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165:575–582.e573

    Article  Google Scholar 

  17. Krumholz HM, Baker DW, Ashton CM et al (2000) Evaluating quality of care for patients with heart failure. Circulation 101:E122–E140

    Article  CAS  PubMed  Google Scholar 

  18. Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31:1281–1357

  19. McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869

    Article  CAS  PubMed  Google Scholar 

  20. McMurray JJ, Holman RR, Haffner SM et al (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477–1490

  21. Neumann T, Biermann J, Erbel R et al (2009) Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int 106:269–275

    PubMed Central  PubMed  Google Scholar 

  22. Silverberg DS, Wexler D, Iaina A et al (2006) The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 26:296–306

    Article  PubMed  Google Scholar 

  23. Solomon SD, Dobson J, Pocock S et al (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116:1482–1487

    Article  PubMed  Google Scholar 

  24. Stork S, Faller H, Schowalter M et al (2009) Evidence-based disease management in patients with heart failure (HeartNetCare-HF Würzburg). Dtsch Med Wochenschr 134:773–776

    Article  CAS  PubMed  Google Scholar 

  25. Stork S, Hense HW, Zentgraf C et al (2008) Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail 10:1236–1245

    Article  PubMed  Google Scholar 

  26. Swedberg K, Young JB, Anand IS et al (2013) Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 368:1210–1219

  27. Takeda A, Taylor SJ, Taylor RS et al (2012) Clinical service organisation for heart failure. Cochrane Database Syst Rev 9:CD002752

    PubMed  Google Scholar 

  28. Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:e240–e327

    Article  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. C. Feldmann, G. Ertl und C.E. Angermann geben an, dass kein Interessenkonflikt besteht. Die wissenschaftliche Arbeit der Autoren wird oder wurde von folgenden Firmen/Einrichtungen finanziell unterstützt: Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft, Lundbeck, Merck, Sharp & Dohme, Novartis, Pfizer, ResMed, Roche, Siemens und Vifor. C.E. Angermann erhält Berater- oder Vortragshonorare von den Firmen Bayer, Biotronik, Merck, Sharp & Dohme, Servier, Novartis, Pfizer und ResMed. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C.E. Angermann.

Additional information

Der Erinnerung an Prof. Dr. Dr. h. c. mult. Kurt Kochsiek gewidmet.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feldmann, C., Ertl, G. & Angermann, C. Ganzheitliche Behandlung der chronischen Herzinsuffizienz. Internist 55, 676–686 (2014). https://doi.org/10.1007/s00108-013-3427-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-013-3427-0

Schlüsselwörter

Keywords

Navigation